Novo Nordisk discovered how to optimize their mAb process

One of the key drivers for change in biopharmaceutical manufacturing is the need to reduce costs and increase the robustness and flexibility of manufacturing options. Optimization of downstream purification processes is an important step towards achieving these goals. One way to introduce cost and time efficiencies is with in-line concentration of dilute solutions before downstream processing steps.

Single-pass tangential flow filtration (SPTFF) technology has previously been used to cope with monoclonal antibody (mAb) production challenges. This study was built on behalf of Novo Nordisk to investigate the performance and scale-up possibilities for in-line concentration on a mAb production platform. It used a patented SPTFF system designed by Pall Biotech.

Get the case study – and discover the benefits for you too!

Subscribe to our FREE newsletter

We will not sell or give your information to a third party. See our Privacy Policy